Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
43.08
-0.25 (-0.58%)
Oct 27, 2025, 4:00 PM EDT - Market closed
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $12.46M in the quarter ending June 30, 2025, with 44.57% growth. This brings the company's revenue in the last twelve months to $40.88M, up 30.57% year-over-year. In the year 2024, Agios Pharmaceuticals had annual revenue of $36.50M with 36.07% growth.
Revenue (ttm)
$40.88M
Revenue Growth
+30.57%
P/S Ratio
60.45
Revenue / Employee
$83,760
Employees
488
Market Cap
2.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.50M | 9.68M | 36.07% |
| Dec 31, 2023 | 26.82M | 12.58M | 88.36% |
| Dec 31, 2022 | 14.24M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AGIO News
- 10 days ago - Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia - Business Wire
- 10 days ago - Agios' PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia - GlobeNewsWire
- 11 days ago - Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET - GlobeNewsWire
- 5 weeks ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 6 weeks ago - AGIO Investors Have Opportunity to Join Agios Pharmaceuticals, Inc. Fraud Investigation With the Schall Law Firm - Business Wire
- 7 weeks ago - Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive - Seeking Alpha
- 7 weeks ago - Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
- 7 weeks ago - FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga